Erick Lucera - 04 Mar 2025 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Reporting relationship: EVP, CHIEF FINANCIAL OFFICER
Issuer ticker: EDIT
Reported as of: 04 Mar 2025
Net transaction value: -$7,030
SEC form: 4
Accepted by SEC: 05 Mar 2025, 16:44:08 UTC
Prior SEC filing: 26 Nov 2024
Next SEC filing: 27 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Erick Lucera

Key filing fact

Erick Lucera filed Form 4 for Editas Medicine, Inc. (EDIT) on 05 Mar 2025.

Key facts

This page summarizes Erick Lucera's Form 4 filing for Editas Medicine, Inc. (EDIT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Mar 2025, 16:44.

Change

Previous filing in this sequence was filed on 26 Nov 2024.
Current net transaction value: -$7,030.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EDIT transaction

Common Stock

Sale

Transaction value: $7,030
Shares: -4,109
Change %: -3.5%
Price: $1.71
Shares after: 112,720
Date: 04 Mar 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 12, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 3, 2025. The sale does not represent a discretionary trade by the Reporting Person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $1.7107 to $1.7150 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.